Merck and moderna announce exercise of option by merck for joint development and commercialization of investigational personalized cancer vaccine

Companies on track to report data from the ongoing phase 2 trial of mrna-4157/v940 in combination with keytruda® as adjuvant therapy in high-risk melanoma in 4q 2022 cambridge, ma and rahway, nj / accesswire / october 12, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and merck (nyse:mrk), known as msd outside the united states and canada, today announced that merck has exercised its option to jointly develop and commercialize personalized cancer vaccine (pcv) mrna-4157/v940 pursuant to the terms of its existing collaboration and license agreement. mrna-4157/v940 is currently being evaluated in combination with keytruda, merck's anti-pd-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a phase 2 clinical trial being conducted by moderna.
MRNA Ratings Summary
MRNA Quant Ranking